Interim Vice Dean, Research
With the University of Toronto Bonelab, Professor Morris Manolson’s research explores the conditions leading to pathological bone loss, and develops therapeutics to prevent it. Professor Manolson has recently won a CIHR grant to study V-ATPases, the body’s “acid pumps,” a study which may reveal novel new therapeutic targets for diseases ranging from arthritis to cancer.
Canadian Institute of Health Research-Institute for Gender Health/Ontario Women’s Health Council Senior Investigator Award (2008-13)
Canadian Institute of Health Research-Institute of Musculoskeletal Health and Arthritis (IMHA) Quality of Life Award (2007)
Esmail S, Yao Y, Kartner N, Li J, Reithmeier RA, Manolson MF. N-Linked Glycosylation Is Required for Vacuolar H+ -ATPase (V-ATPase) a4 Subunit Stability, Assembly, and Cell Surface Expression.J Cell Biochem. 2016 Dec;117(12):2757-2768. doi: 10.1002/jcb.25574.
Crasto GJ, Kartner N, Reznik N, Spatafora MV, Chen H, Williams R, Burns PN, Clokie C, Manolson MF, Peel SA. Controlled bone formation using ultrasound-triggered release of BMP-2 from liposomes. J Control Release. 2016 Sep 28;243:99-108. doi: 10.1016/j.jconrel.2016.09.032.
Kartner N, Manolson MF. Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H(+)-ATPase as an emerging target. Expert Opin Drug Discov. 2014 May;9(5):505-22. doi: 10.1517/17460441.2014.902155. Review.